Dividend Watch: GSK Still Yielding More Than 4%

In its Q3 2024 earnings results, pharmaceutical stock confirmed the next payout of 15p to be paid in January.

Christopher Johnson 8 November, 2024 | 10:22AM
Facebook Twitter LinkedIn

 

 


In its third quarter results of 2024, pharmaceutical giant, Glaxo Smith Kline, confirmed it would pay a quarterly dividend of 15p.

The business expects to pay out a full year dividend of 60p due to its total sales reaching £8 billion.

However, Morningstar believes that GSK’s dividends historically have been a bit too high.

Over the past five years, GSK has paid out a dividend at roughly 70% of normalized earnings.

This may have reduced the firm’s ability to reinvest in the company through internal R&D and external acquisitions of new drugs.

However, in its Q3 report, GSK said it made good progress in R&D, with regulatory approvals and high rates of efficacy of its new drugs.

Sales of its specialty medicines grew 19% year on year. Performance was strong across therapeutic areas, with HIV growing 12%, respiratory and immunology growing 14%, and oncology growing by 94%.

Yet, the business saw the sales of vaccines decline 15% year on year driven by a drop in sales for its Shingles’ vaccine and a decline of 72% for sales in its Arexvy drug which combats respiratory tract disease.

GSK’s share price is trading at £13.74 below Morningstar’s Fair Value Estimate of £22.


The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar's editorial policies.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

About Author

Christopher Johnson  is data journalist at Morningstar

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures